AQST Relative Valuation
AQST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AQST is overvalued; if below, it's undervalued.
Historical Valuation
Aquestive Therapeutics Inc (AQST) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.90 is considered Overvalued compared with the five-year average of -4.62. The fair price of Aquestive Therapeutics Inc (AQST) is between 0.90 to 3.23 according to relative valuation methord. Compared to the current price of 6.21 USD , Aquestive Therapeutics Inc is Overvalued By 92.55%.
Relative Value
Fair Zone
0.90-3.23
Current Price：6.21
92.55%
Overvalued
-9.94
PE
1Y
3Y
5Y
-9.42
EV/EBITDA
Aquestive Therapeutics Inc. (AQST) has a current EV/EBITDA of -9.42. The 5-year average EV/EBITDA is -6.56. The thresholds are as follows: Strongly Undervalued below -13.88, Undervalued between -13.88 and -10.22, Fairly Valued between -2.90 and -10.22, Overvalued between -2.90 and 0.76, and Strongly Overvalued above 0.76. The current Forward EV/EBITDA of -9.42 falls within the Historic Trend Line -Fairly Valued range.
-10.66
EV/EBIT
Aquestive Therapeutics Inc. (AQST) has a current EV/EBIT of -10.66. The 5-year average EV/EBIT is -5.79. The thresholds are as follows: Strongly Undervalued below -12.05, Undervalued between -12.05 and -8.92, Fairly Valued between -2.65 and -8.92, Overvalued between -2.65 and 0.48, and Strongly Overvalued above 0.48. The current Forward EV/EBIT of -10.66 falls within the Undervalued range.
13.90
PS
Aquestive Therapeutics Inc. (AQST) has a current PS of 13.90. The 5-year average PS is 4.39. The thresholds are as follows: Strongly Undervalued below -2.12, Undervalued between -2.12 and 1.14, Fairly Valued between 7.65 and 1.14, Overvalued between 7.65 and 10.90, and Strongly Overvalued above 10.90. The current Forward PS of 13.90 falls within the Strongly Overvalued range.
-14.98
P/OCF
Aquestive Therapeutics Inc. (AQST) has a current P/OCF of -14.98. The 5-year average P/OCF is -5.19. The thresholds are as follows: Strongly Undervalued below -14.26, Undervalued between -14.26 and -9.72, Fairly Valued between -0.65 and -9.72, Overvalued between -0.65 and 3.89, and Strongly Overvalued above 3.89. The current Forward P/OCF of -14.98 falls within the Strongly Undervalued range.
-24.20
P/FCF
Aquestive Therapeutics Inc. (AQST) has a current P/FCF of -24.20. The 5-year average P/FCF is -8.87. The thresholds are as follows: Strongly Undervalued below -24.44, Undervalued between -24.44 and -16.66, Fairly Valued between -1.09 and -16.66, Overvalued between -1.09 and 6.70, and Strongly Overvalued above 6.70. The current Forward P/FCF of -24.20 falls within the Undervalued range.
Aquestive Therapeutics Inc (AQST) has a current Price-to-Book (P/B) ratio of -190.98. Compared to its 3-year average P/B ratio of -20.55 , the current P/B ratio is approximately 829.16% higher. Relative to its 5-year average P/B ratio of -13.04, the current P/B ratio is about 1364.01% higher. Aquestive Therapeutics Inc (AQST) has a Forward Free Cash Flow (FCF) yield of approximately -6.47%. Compared to its 3-year average FCF yield of -5.42%, the current FCF yield is approximately 19.45% lower. Relative to its 5-year average FCF yield of -19.85% , the current FCF yield is about -67.39% lower.
-190.98
P/B
Median3y
-20.55
Median5y
-13.04
-6.47
FCF Yield
Median3y
-5.42
Median5y
-19.85
Competitors Valuation Multiple
The average P/S ratio for AQST's competitors is 4.78, providing a benchmark for relative valuation. Aquestive Therapeutics Inc Corp (AQST) exhibits a P/S ratio of 13.90, which is 190.46% above the industry average. Given its robust revenue growth of -5.43%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AQST increased by 106.29% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.46 to -9.28.
The secondary factor is the Margin Expansion, contributed 41.91%to the performance.
Overall, the performance of AQST in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
RZLT
Rezolute Inc
2.37USD
0.85%
BRBS
Blue Ridge Bankshares Inc
4.35USD
1.87%
GAU
Galiano Gold Inc
2.65USD
0.38%
CCCC
C4 Therapeutics Inc
2.19USD
-1.35%
ARQ
Arq Inc
3.66USD
2.81%
PCYO
Pure Cycle Corp
11.17USD
4.78%
FRST
Primis Financial Corp
13.42USD
2.99%
IMMR
Immersion Corp
6.49USD
1.72%
RGP
Resources Connection Inc
4.5USD
-14.61%
IMMP
Immutep Ltd
2.98USD
-1.97%
Frequently Asked Questions
Is Aquestive Therapeutics Inc (AQST) currently overvalued or undervalued?
Aquestive Therapeutics Inc (AQST) is now in the Overvalued zone, suggesting that its current forward PS ratio of 13.90 is considered Overvalued compared with the five-year average of -4.62. The fair price of Aquestive Therapeutics Inc (AQST) is between 0.90 to 3.23 according to relative valuation methord. Compared to the current price of 6.21 USD , Aquestive Therapeutics Inc is Overvalued By 92.55% .
What is Aquestive Therapeutics Inc (AQST) fair value?
AQST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aquestive Therapeutics Inc (AQST) is between 0.90 to 3.23 according to relative valuation methord.
How does AQST's valuation metrics compare to the industry average?
The average P/S ratio for AQST's competitors is 4.78, providing a benchmark for relative valuation. Aquestive Therapeutics Inc Corp (AQST) exhibits a P/S ratio of 13.90, which is 190.46% above the industry average. Given its robust revenue growth of -5.43%, this premium appears unsustainable.
What is the current P/B ratio for Aquestive Therapeutics Inc (AQST) as of Jan 08 2026?
As of Jan 08 2026, Aquestive Therapeutics Inc (AQST) has a P/B ratio of -190.98. This indicates that the market values AQST at -190.98 times its book value.
What is the current FCF Yield for Aquestive Therapeutics Inc (AQST) as of Jan 08 2026?
As of Jan 08 2026, Aquestive Therapeutics Inc (AQST) has a FCF Yield of -6.47%. This means that for every dollar of Aquestive Therapeutics Inc’s market capitalization, the company generates -6.47 cents in free cash flow.
What is the current Forward P/E ratio for Aquestive Therapeutics Inc (AQST) as of Jan 08 2026?
As of Jan 08 2026, Aquestive Therapeutics Inc (AQST) has a Forward P/E ratio of -9.94. This means the market is willing to pay $-9.94 for every dollar of Aquestive Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aquestive Therapeutics Inc (AQST) as of Jan 08 2026?
As of Jan 08 2026, Aquestive Therapeutics Inc (AQST) has a Forward P/S ratio of 13.90. This means the market is valuing AQST at $13.90 for every dollar of expected revenue over the next 12 months.